Evaluation of the system Axima/Saramis MALDI-TOF MS bioMérieux in a clinical laboratory


Submitted: 13 February 2014
Accepted: 13 February 2014
Published: 31 March 2012
Abstract Views: 2719
PDF: 1819
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Authors

Introduction. Mass Spectrometry technology “Matrix-assisted laser desorption Ionisation/Time-of-Flight (MALDI-TOF MS)” offers a promising new approach for identification of bacteria and fungi of clinical interest. The objective of this study is to evaluate the comparison of microbial identifications obtained with the system Axima/Saramis bioMérieux and identifications obtained by conventional manual or automatic (Vitek 2- bioMérieux).The work was divided into a pilot phase in which the staff has been trained and are set instrument parameters and an operational phase. Methods. MALDI-TOF is a system for the detection and identification of species-specific highly conserved proteins (ribosomal DNA and ligands). Part of a bacterial colony, is deposited on a polymeric substrate, extracted by the addition of the matrix (acid α-Cyano-4-hydroxycinnamic) and analyzed by MALDI-TOF.The mass spectra obtained are compared with the database Saramis (Anagnostec) containing the reference spectra of common pathogens. Results. During the pilot phase were analyzed 303 microorganisms (281 bacteria and 22 fungi), of which 207 (68.3%) correctly identified to species level, 35 (11.6%) identified as a species but not the main one and 49 (16.2%) did not identified. In the second phase of the study were analyzed microorganisms 1417 (1341 bacteria and 76 fungi) in a period of 60 days in 1240 (87.5%) correctly identified to species level, 121 (8.5%) identified as a species but not the main one and 41 (2.9%) unidentified. Conclusions. By reducing the response time (15 min/1 sample), the use of MALDI-TOF system, bioMérieux facilitates the workflow in the clinical laboratory, and positive impact on length of stay and costs. In addition, the rapid identification of yeasts at the species level is definitely a value added important and independent execution of test sensitivity. Finally, a good operator training translates into improved overall system performance.

Mattei, R., Vicario, C., Nardone, M., & Savarino, A. (2012). Evaluation of the system Axima/Saramis MALDI-TOF MS bioMérieux in a clinical laboratory. Microbiologia Medica, 27(1). https://doi.org/10.4081/mm.2012.2331

Downloads

Download data is not yet available.

Citations